- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
2/23/17 4:15 pm ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced the election of Ronald E. Blaylock to its Board of Directors, effective immediately. Mr. Blaylock was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board. Mr. Blaylock, 57, is the Founder, Managing Partner of GenNx360 Capital Partners, a private equity firm focused on investing in industrial and business services companies in the U.S. middle market, since 2006.more...
Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration2/21/17 8:00 am EST
Application Requests Approval for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in AdultsNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that a Biologics License Application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). Inotuzumab ozogamicin is being evaluated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Inotuzumab ozogamicin received Breakthrough Therapy designation frommore...
New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a2/17/17 12:00 pm EST
Pfizer in partnership with Celltrion Healthcare presents new data for INFLECTRA in Crohn’s diseaseNEW YORK--(BUSINESS WIRE)--Data announced jointly today by Pfizer Inc. (NYSE:PFE) and Celltrion Healthcare, at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO), showed that for patients with moderate-to-severe Crohn’s disease (CD), treatment with INFLECTRA (infliximab CT-P13) has similar efficacy and safety to treatment with REMICADE (infliximab).1 The randomized 54 week clinical trial (RCT)2 in 214 patients met its primary end pointmore...
Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab)2/16/17 8:00 am ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ® (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid arthritis (RA). ORAL Strategy is the first trial to compare a JAK inhibitor as monotherapy or in combination with methotrexate (MTX) versus adalimumab (Humira) plus MTX in MTX inadequate responders using ACR50 at Month 6 as the primary endpoint.more...
Relationship Expert Teams Up with Pfizer to Address Intimacy and Relationship Issues for People Living with Chronic Diseases2/9/17 8:30 am EST
Logan Levkoff, Ph.D., addresses tough topics for those living with rheumatoid arthritis on Arthritis.comNEW YORK--(BUSINESS WIRE)--Nationally-recognized relationship expert and author, Logan Levkoff, Ph.D., has partnered with Pfizer Inc. (NYSE:PFE) to fill a void in information available to people living with chronic diseases: relationship advice. Levkoff will address the topics of relationships and intimacy for those living with a chronic condition, like rheumatoid arthritis (RA), on the newly re-launched Arthritis.com site. The website is a place where people living withmore...
1/31/17 6:45 am EST
PROVIDES 2017 FINANCIAL GUIDANCE
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2016 and provided 2017 financial guidance. Pfizer manages its commercial operations through two distinct businesses: Pfizer Innovative Health (IH)(3) (formerly the Innovative Products business) and Pfizer Essential Health (EH)(3)(4) (formerly the Established Products business). Financial results for each of these businesses are presented in the Operatingmore...
- Full-Year 2016 Revenues of $52.8 Billion, Reflecting 11% Operational Growth; Full-Year 2016 Revenues for Pfizer Standalone (Excluding Legacy Hospira and Legacy Medivation) of $48.1 Billion, Reflecting 5% Operational Growth
- Fourth-Quarter 2016 Revenues of $13.6 Billion, Reflecting 1% Operational Decline, Unfavorably Impacted by Four Fewer U.S. Selling Days and Three Fewer International Selling Days Compared to the Prior-Year Quarter; Fourth-Quarter 2016 Pfizer Standalone Revenues of $12.3 Billion, Reflecting 2% Operational Decline
- Full-Year 2016 Reported Diluted EPS(1) of $1.17, Adjusted Diluted EPS(2) of $2.40; Fourth-Quarter 2016 Reported Diluted EPS(1) of $0.13, Adjusted Diluted EPS(2) of $0.47
- Provides 2017 Financial Guidance, Including Revenues of $52.0 to $54.0 Billion and Adjusted Diluted EPS(2) of $2.50 to $2.60; Reflects Pending Disposition of Hospira Infusion Systems, which Contributed $1.2 Billion of Revenues and $0.03 of Adjusted Diluted EPS(2) in 2016
Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ® (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis1/27/17 7:00 am ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) for the treatment of patients with moderate to severe active rheumatoid arthritis (RA). The CHMP’s opinion will now be sent to the European Commission (EC) for final decision. If approved, XELJANZ in combinationmore...
Pfizer Announces Positive Top-Line Results from Phase 2 Study of Investigational Clostridium difficile Vaccine for the Prevention of C. difficile Infection1/26/17 8:00 am EST
Pfizer’s C. difficile Vaccine Candidate to Commence Phase 3 Study in First Half of 2017
C. difficile is an Increasing Worldwide Concern Associated with Approximately 29,000 Annual Deaths in the U.S. AloneNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the Phase 2 study evaluating the Company’s Clostridium difficile (C. difficile) vaccine candidate, PF-06425090, provided positive data, based on a pre-planned interim analysis. The randomized Phase 2 study (NCT02561195) examined the safety, tolerability, and immunogenicity of the vaccine in healthy adults 65 to 85 years of age. Pfizer’s vaccine candidate is designed to help prevent C. difficilemore...
Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab)1/5/17 8:30 am EST
Marks Pfizer’s third proposed biosimilar pipeline molecule 2 to report positive top-line data results within the past four monthsNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the comparative, confirmatory REFLECTIONS B538-02 study met its primary objective by demonstrating equivalent efficacy as measured by the American College of Rheumatology 20 (ACR20) response rate at Week 12. This trial is evaluating the efficacy, safety, and immunogenicity of PF-06410293 compared to Humira® (adalimumab), each taken in combination with methotrexate, in patients with moderate to severemore...
1/3/17 11:00 am ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 31, 2017. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2016 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web sitemore...